Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, China
Hepatic Surgery Clinical Research Centre of Hubei, China
Information provided by:
Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00733200
First received: August 8, 2008
Last updated: December 10, 2009
Last verified: August 2008
  Purpose

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.


Condition Intervention
Cholangiocarcinoma
Surgical Treatment
Hepatectomy
Procedure: Minor or Major Liver Resection

Study Type: Interventional
Official Title: Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

Resource links provided by NLM:


Further study details as provided by Huazhong University of Science and Technology:

Primary Outcome Measures:
  • On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade.

Arms Assigned Interventions
No Intervention: Control group Procedure: Minor or Major Liver Resection

Detailed Description:

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC).

Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies.

Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent. Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

  Eligibility

Ages Eligible for Study:   26 Years to 72 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion Criteria:

  • not in accordance with the above criteria
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00733200     History of Changes
Other Study ID Numbers: chenxp002
Study First Received: August 8, 2008
Last Updated: December 10, 2009
Health Authority: China: Food and Drug Administration

Keywords provided by Huazhong University of Science and Technology:
Minor Liver Resection
Major Liver Resection
Hilar

Additional relevant MeSH terms:
Cholangiocarcinoma
Klatskin's Tumor
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on April 15, 2014